VSTM

Verastem, Inc.

7 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 26

Approval of amended equity incentive and stock purchase plans increases potential for share dilution.

dilution risk

60%

neutralMay 26

Re-election of Class II directors maintains current leadership stability.

management change

30%

bullishMay 7

First-ever product revenue of $18.7 million recorded following FDA approval.

earnings beat

70%

bullishMay 7

Achieved high gross margins exceeding 83% on initial commercial sales.

margin expansion

80%

neutralMay 7

Cleaned up capital structure through the exercise of warrants and elimination of warrant liability.

capital raise

50%

bearishMay 7

Going concern warning suggests high probability of future equity offerings to fund Phase 2 trials.

dilution risk

90%

bullishMay 7

First-ever product revenue of $18.7 million recorded following FDA approval.

earnings beat

70%

bullishMay 7

Achieved high gross margins exceeding 83% on initial commercial sales.

margin expansion

80%

neutralMay 7

Cleaned up capital structure through the exercise of warrants and elimination of warrant liability.

capital raise

50%

bearishMay 7

Going concern warning suggests high probability of future equity offerings to fund Phase 2 trials.

dilution risk

90%

bullishMay 7

First-ever product revenue of $18.7 million recorded following FDA approval.

earnings beat

70%

bullishMay 7

Achieved high gross margins exceeding 83% on initial commercial sales.

margin expansion

80%

neutralMay 7

Cleaned up capital structure through the exercise of warrants and elimination of warrant liability.

capital raise

50%

bearishMay 7

Going concern warning suggests high probability of future equity offerings to fund Phase 2 trials.

dilution risk

90%

bullishMay 7

First-ever product revenue of $18.7 million recorded following FDA approval.

earnings beat

70%

bullishMay 7

Achieved high gross margins exceeding 83% on initial commercial sales.

margin expansion

80%

neutralMay 7

Cleaned up capital structure through the exercise of warrants and elimination of warrant liability.

capital raise

50%

bearishMay 7

Going concern warning suggests high probability of future equity offerings to fund Phase 2 trials.

dilution risk

90%

bullishMay 7

First-ever product revenue of $18.7 million recorded following FDA approval.

earnings beat

70%

bullishMay 7

Achieved high gross margins exceeding 83% on initial commercial sales.

margin expansion

80%

neutralMay 7

Cleaned up capital structure through the exercise of warrants and elimination of warrant liability.

capital raise

50%

bearishMay 7

Going concern warning suggests high probability of future equity offerings to fund Phase 2 trials.

dilution risk

90%

bullishMay 7

First-ever product revenue of $18.7 million recorded following FDA approval.

earnings beat

70%

bullishMay 7

Achieved high gross margins exceeding 83% on initial commercial sales.

margin expansion

80%

neutralMay 7

Cleaned up capital structure through the exercise of warrants and elimination of warrant liability.

capital raise

50%

bearishMay 7

Going concern warning suggests high probability of future equity offerings to fund Phase 2 trials.

dilution risk

90%

Filing History

8-KMay 26, 2026

The 8-K filing confirms that Verastem has cleared its immediate governance hurdles, but the victory is nuanced. While the board was re-elected and key incentive plans were passed, the disparity in vote totals and the high volume of non-votes highlight a tension between management's desire for growth and the market's concern over capital preservation. Investors are now left to determine if these approvals represent a stable foundation for clinical acceleration or a precursor to further equity dilution as the company chases its next major milestone.

10-QMay 7, 2026

The Q1 2026 filing presents a stark contrast between commercial proof-of-concept and financial instability. On one hand, the generation of $18.7 million in revenue proves that Verastem's lead asset has a viable market and high margin potential. On the other hand, the management's admission of substantial doubt regarding the company's ability to continue as a going concern serves as a critical warning for investors. The company is essentially racing to prove the clinical value of its VS-7375 program before its current cash reserves are exhausted by the very trials intended to drive future value. Ultimately, the investment case hinges on whether the commercial ramp of AVMAPKI FAKZYNJA can accelerate fast enough to offset the massive capital requirements of the TARGET-D program. While the technical data remains promising, the financial risk is acute, leaving Verastem in a high-stakes transition period where clinical success must be matched by aggressive capital management or further dilutive financing.